14.77
Schlusskurs vom Vortag:
$14.66
Offen:
$14.75
24-Stunden-Volumen:
35,820
Relative Volume:
0.09
Marktkapitalisierung:
$744.34M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-16.05
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
+3.36%
1M Leistung:
+2.57%
6M Leistung:
+42.53%
1J Leistung:
+78.50%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TBPH
Theravance Biopharma Inc
|
14.78 | 738.30M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.74 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.57 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.54 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.40 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.00 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Will a bounce in Theravance Biopharma Inc. offer an exitQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
Can Theravance Biopharma Inc. stock maintain operating marginsWeekly Trend Report & Community Trade Idea Sharing Platform - newser.com
What consensus target says about Theravance Biopharma Inc. (0TB) stockInflation Watch & Verified Short-Term Trading Plans - newser.com
Is Theravance Biopharma Inc. (0TB) stock a momentum leaderTreasury Yields & Safe Capital Growth Tips - newser.com
Can Theravance Biopharma Inc. (0TB) stock sustain revenue momentum2025 Dividend Review & Community Driven Trade Alerts - newser.com
Can Theravance Biopharma Inc. stock deliver consistent earnings growth2025 EndofYear Setup & Trade Opportunity Analysis Reports - newser.com
Can Theravance Biopharma Inc. (0TB) stock hit consensus price targets2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
Why Theravance Biopharma Inc. (0TB) stock benefits from AI revolutionMarket Performance Recap & Reliable Breakout Forecasts - newser.com
Why Theravance Biopharma Inc. stock is in analyst buy zone2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Why Theravance Biopharma Inc. (0TB) stock remains stableJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Theravance Biopharma Inc. stock trendline breakdownJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
Will Theravance Biopharma Inc. stock see insider buyingAnalyst Upgrade & Technical Pattern Based Signals - newser.com
Can Theravance Biopharma Inc. stock attract ESG capital inflowsJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
How to escape a deep drawdown in Theravance Biopharma Inc.July 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
What to expect from Theravance Biopharma Inc. in the next 30 daysIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
Theravance Biopharma, Inc. (TBPH) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? - sharewise.com
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - Lelezard
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):